Ocugen, Inc.

Pursuing Innovative Ocular Biotherapeutics

Ocugen, Inc.
  • About
    +
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Founders
  • Vaccine
    +
    • Vaccine Overview
    • Scientific Advisory Board
    • Publications
  • Pipeline
    +
    • Pipeline Overview
    • Modifier Gene Therapy Platform
    • OCU400
    • OCU410
    • OCU200
    • COVAXIN™
  • News
    +
    • News
    • Events
    • Press Releases
  • Investors
    +
    • Investor Overview
    • Stock Information
      +
      • Historic Price Lookup
      • Investor Calculator
      • Analyst Coverage
    • Financial Information
      +
      • SEC Filings
      • Financial Reports
      • Quarterly Reports
    • Presentations
    • Corporate Governance
    • Investor Resources
      +
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • Contact
Contact

Scientific Publications

  • Vaccine Overview
  • Vaccine Scientific Advisory Board
  • Scientific Publications

Preclinical Product Development
https://www.biorxiv.org/content/10.1101/2020.09.09.285445v2

Animal Challenge Studies – Hamsters
https://www.researchsquare.com/article/rs-76768/v1

Animal Challenge Studies – Rhesus Macaques
https://vaccine.icmr.org.in/images/pdf/934dd262-405d-43c6-af12-e59901253050.pdf

Human Clinical Trials – Phase I
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30942-7/fulltext

Human Clinical Trials – Phase II
https://www.medrxiv.org/content/10.1101/2020.12.21.20248643v1

COVAXIN effectively neutralizes UK variant of SARS-CoV-2 reducing the possibility of mutant virus escape
https://www.biorxiv.org/content/10.1101/2021.01.26.426986v1.full.pdf

Ocugen, Inc.

Ocugen, Inc.

  • 263 Great Valley Parkway
    Malvern, PA 19355
  • 484.328.4701

Quick Links

  • About
  • News
  • Events
  • Press
  • Pipeline
  • Investors
  • Careers
  • Contact

Keep In Touch


© 2021 Ocugen, Inc. All Rights Reserved.